Research ArticleTheranostics
Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial
Wolfgang P. Fendler, Justin Ferdinandus, Johannes Czernin, Matthias Eiber, Robert R. Flavell, Spencer C. Behr, I-Wei K. Wu, Courtney Lawhn-Heath, Miguel H. Pampaloni, Robert E. Reiter, Matthew B. Rettig, Jeannine Gartmann, Vishnu Murthy, Roger Slavik, Peter R. Carroll, Ken Herrmann, Jeremie Calais and Thomas A. Hope
Journal of Nuclear Medicine December 2020, 61 (12) 1793-1799; DOI: https://doi.org/10.2967/jnumed.120.242180
Wolfgang P. Fendler
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
2Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Germany
Justin Ferdinandus
2Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Germany
Johannes Czernin
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
Matthias Eiber
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
3Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
Robert R. Flavell
4Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
Spencer C. Behr
4Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
I-Wei K. Wu
4Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
Courtney Lawhn-Heath
4Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
Miguel H. Pampaloni
4Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
Robert E. Reiter
5Department of Urology, UCLA Medical Center, UCLA, Los Angeles, California
Matthew B. Rettig
5Department of Urology, UCLA Medical Center, UCLA, Los Angeles, California
6Division of Hematology/Oncology, Department of Medicine, UCLA, and Division of Hematology/Oncology, Department of Medicine, VA Greater Los Angeles, Los Angeles, California; and
Jeannine Gartmann
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
Vishnu Murthy
4Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
Roger Slavik
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
Peter R. Carroll
7Department of Urology, University of California, San Francisco, San Francisco, California
Ken Herrmann
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
2Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Germany
Jeremie Calais
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
Thomas A. Hope
4Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 61, Issue 12
December 1, 2020
Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial
Wolfgang P. Fendler, Justin Ferdinandus, Johannes Czernin, Matthias Eiber, Robert R. Flavell, Spencer C. Behr, I-Wei K. Wu, Courtney Lawhn-Heath, Miguel H. Pampaloni, Robert E. Reiter, Matthew B. Rettig, Jeannine Gartmann, Vishnu Murthy, Roger Slavik, Peter R. Carroll, Ken Herrmann, Jeremie Calais, Thomas A. Hope
Journal of Nuclear Medicine Dec 2020, 61 (12) 1793-1799; DOI: 10.2967/jnumed.120.242180
Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial
Wolfgang P. Fendler, Justin Ferdinandus, Johannes Czernin, Matthias Eiber, Robert R. Flavell, Spencer C. Behr, I-Wei K. Wu, Courtney Lawhn-Heath, Miguel H. Pampaloni, Robert E. Reiter, Matthew B. Rettig, Jeannine Gartmann, Vishnu Murthy, Roger Slavik, Peter R. Carroll, Ken Herrmann, Jeremie Calais, Thomas A. Hope
Journal of Nuclear Medicine Dec 2020, 61 (12) 1793-1799; DOI: 10.2967/jnumed.120.242180
Jump to section
Related Articles
Cited By...
- Predicting Outcomes of Indeterminate Bone Lesions on 18F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer
- Feasibility of 99mTc-MIP-1404 for SPECT/CT Imaging and Subsequent PSMA-Radioguided Surgery in Early Biochemically Recurrent Prostate Cancer: A Case Series of 9 Patients
- PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study
- The Added Value of 18F-FDG PET/CT Compared with 68Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer
- 68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial
- Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging
- A Phase II, Open-Label Study to Assess Safety and Management Change Using 68Ga-THP PSMA PET/CT in Patients with High-Risk Primary Prostate Cancer or Biochemical Recurrence After Radical Treatment: The PRONOUNCED Study
- Detection Efficacy of 18F-rhPSMA-7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment